Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M108,708Revenue (TTM) $M37,533Net Margin (%)3.3Altman Z-Score1.4
Enterprise Value $M132,641EPS (TTM) $0.2Operating Margin %9.3Piotroski F-Score5
P/E(ttm)88.0Beneish M-Score-2.7Pre-tax Margin (%)7.0Higher ROA y-yN
Price/Book80.010-y EBITDA Growth Rate %-1.9Quick Ratio0.6Cash flow > EarningsY
Price/Sales2.95-y EBITDA Growth Rate %-8.5Current Ratio0.9Lower Leverage y-yY
Price/Free Cash Flow19.8y-y EBITDA Growth Rate %-65.9ROA % (ttm)1.6Higher Current Ratio y-yN
Dividend Yield %4.9PEG--ROE % (ttm)46.7Less Shares Outstanding y-yN
Payout Ratio %430Shares Outstanding M5,368ROIC % (ttm)8.7Gross Margin Increase y-yY

Gurus Latest Trades with GLAXF

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

GLAXF is held by these investors:



GLAXF: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLCFormer 10% Owner 2015-02-23Sell503,150$22-6.18view
GLAXOSMITHKLINE PLC10% Owner 2014-12-18Sell50,000$21.14-2.37view
GLAXOSMITHKLINE PLCFormer 10% Owner (1) 2014-10-27Sell11,315,825$5.29290.17view
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$1272view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$1447.43view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$1272view

Quarterly/Annual Reports about GLAXF:

    News about GLAXF:

    Articles On GuruFocus.com
    Pernix: An Investor's Rationale to Staying Long Mar 23 2017 
    Jeff Auxier Reduces, Exits Multiple Positions in 4th Quarter Mar 22 2017 
    Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
    If You Want Yield, Look to the UK Feb 19 2017 
    Flood of News Presents Buying Opportunity Jan 17 2017 
    Gilead Sciences Must Answer to Investors After a Disappointing 2016 Jan 05 2017 
    GlaxoSmithKline, Vodafone Hit 3-Year Low Prices Dec 24 2016 
    Asset Sales, New Projects Fuel 6.7% Yield Dec 07 2016 
    Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
    Jeff Auxier Curbs Multiple Positions in 3rd Quarter Dec 01 2016 

    More From Other Websites
    Exploring Novartis’s 2016 Revenue Mar 24 2017
    Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency Mar 23 2017
    Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency Mar 23 2017
    Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency Mar 23 2017
    GSK and Regeneron to mine gene data from 500,000 Britons Mar 22 2017
    GSK and Regeneron to mine gene data from 500,000 Britons Mar 22 2017
    Still Bullish on GlaxoSmithKline Mar 21 2017
    2 safe FTSE 100 shares with dividend yields above 4% Mar 21 2017
    6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017 Mar 21 2017
    Glaxo Files for Label Expansion of Influenza Vaccine in US Mar 16 2017
    Is a GlaxoSmithKline plc buyout back on the cards? Mar 16 2017
    7 Most Popular Diet Pills That Work Fast Without Exercise Mar 15 2017
    Why I’d buy and hold Hikma Pharmaceuticals plc for the next decade Mar 15 2017
    GSK's new female CEO to get 25 percent less after pay policy review Mar 15 2017
    GSK's new female CEO to get 25 percent less after pay policy review Mar 15 2017
    GSK's new female CEO to get 25 percent less after pay policy review Mar 15 2017
    GSK's new female CEO to get 25 pct less after pay policy review Mar 15 2017
    2 shares with explosive growth potential Mar 14 2017
    Couple sue pharma giant for work that led to prison in China Mar 14 2017
    Couple sue pharma giant for work that led to prison in China Mar 14 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)